Schizophrenia a psychological disorder treatment and future aspects

New strategies for treatment of schizophrenia covers Agonists at the glycine and glutamate site of NMDA receptors include the naturally occurring amino acids glycine and D-serine. An analogue of D-serine, called D-cycloserine is also active at the glycine co-agonist site of NMDA receptors. All of these agents have been tested in schizophrenia with evidence that they can reduce negative and/or cognitive symptoms. The GLY-T1 reuptake pump is the major route of inactivation of synaptic glycine, so it is logical to explore the ability of GLY-T1 inhibitors to enhance synaptic actions of glycine, and, thus, of NMDA receptors. GLY-T1 pumps inhibit reuptake of other neurotransmitters which are blocked by a GLY-T1 inhibitor and this increases the synaptic availability of glycine and thus enhances NMDA neurotransmission.

Autorentext

M.Pharm., Ph.D. (Pursuing), Assistant Professor, Department of Pharmaceutical Chemistry, Sardar Patel College of Pharmacy, Bakrol, Anand, Gujarat, India. He has registered for Ph.D. in Gujarat Technological University, Ahmedabad under the guidance of Prof. Dr. Dhrubo Jyoti Sen